To test the hypothesis that fatty liver coexists with hypertriglyceridaemia and/or low HDL-C (86%). Dietary intervention and follow-up (median 24 other metabolic abnormalities of the insulin resistance syndrome, and responds to their amelioration, months), supplemented by oral hypoglycaemic or lipid-lowering drugs as needed, resulted not only in we prospectively studied 48 consecutive patients with chronically elevated liver enzymes and clinical, weight loss (mean 3.7 kg ), decreased fasting blood glucose ( p<0.005) and improvement in serum lipid ultrasound and histological findings consistent with fatty infiltration of the liver. Most of the patients profile ( p<0.02 for both triglycerides or HDL-C) but also in an improvement of serum liver enzymes were overweight or obese (64%) with increased waist circumference which closely relates to visceral in 96%, which became normal in more than half of the patients. Thus, fatty liver was strongly associated fat. Only 10% of the patients had normal glucose tolerance: 44% had diabetes mellitus, 29% impaired with many features of the insulin resistance syndrome, and follow-up revealed a high potential for glucose tolerance, and 17% were hyperinsulinaemic. The most common dyslipidaemia found was reversibility and a benign course.
Introduction
General practitioners and specialists are frequently tion,3 or can be accurately diagnosed non-invasively by ultrasonography (US) of the liver.4 Thus, the confronted with a finding of abnormal liver function tests (LFTs) in patients who are either asymptomatic prevalence of 'milder' forms of fatty liver has not been estimated, but is probably much higher. or have vague abdominal discomfort. In 1980, Ludwig and colleagues described the entity of non-
The underlying conditions and natural course of fatty liver are still controversial. Several studies have alcoholic steatohepatitis (NASH),1 characterized by histological findings of fatty changes with lobular shown an association between NASH and female gender, obesity, glucose intolerance and dyslipidaehepatitis. The prevalence of NASH in patients who undergo liver biopsy is 1.2% to 9%.2 However, mia.5-10 However, there is much variability in the incidence of these factors, ranging from 21% to 75% many more patients with disturbed LFTs and negative results on work-up for other diseases have histoin the case of diabetes or glucose intolerance, 39% to 100% for obesity, and 21% to 81% for hyperlipidlogical findings of fatty infiltration without inflamma-aemia. This variability has led some authors to doubt impaired glucose tolerance (IGT) or diabetes (NIDDM). (IGT, plasma glucose Á7.8 mmol/l at 2 h the importance of the association between NASH and obesity or diabetes.9 These inconsistencies may but <11.1 mmol/l; and diabetes Á11.1 mmol/l). 15 Patients who had a normal glucose response but an be due to incomplete data, since in most of the previous studies, oral glucose tolerance tests (OGTT) elevated fasting insulin level, exceeding the 90th percentile of its distribution among patients with and detailed lipid profiles were not included. Also, some common and confounding conditions such as normal glucose tolerance,16 were diagnosed as hyperinsulinaemic (HI). Lipid determinations were hepatitis C,5-7 some degree of alcohol consumption,8 or increased hepatic iron stores9 were not properly performed twice on fasting blood samples in a Boehringer-Hitachi analyzer using Boehringerruled out in several earlier studies. The natural course of the disease is also unclear, ranging from Mannheim kits. High-density lipoprotein cholesterol (HDL-C) was determined after precipitation of lowbenign,5,7,10 to a progressive course leading to cirrhosis and hepatic failure.9-11 A favourable effect of density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) with phosphotungstate. Cholesterol weight loss on the course of the disease has been suggested, but the data are again inconsistent. 12 concentration was determined in the supernatant. Lipoprotein abnormalities were defined according to The aims of the present study were to perform a comprehensive metabolic work-up, including OGTT the Lipid Research Clinic data for age and gender, i.e. above the 90th percentile for total cholesterol and a detailed anthropometric and lipid profile, in patients with 'primary' fatty liver, and to evaluate and triglyceride levels and below the 10th percentile for HDL-C levels.17 the clinical course, and specifically the effect on the liver, of improvement of the metabolic profile.
Pathology
Liver biopsies were randomly performed and Intervention and follow-up included a detailed history of drugs or alcohol consumption, hepatitis B and C serology, determinaAll patients were referred to a qualified dietician, tion of caeruloplasmin, copper, a 1 -antitrypsin, iron and were followed by visits every 3-4 weeks. and ferritin levels, and autoantibody screening. All Subjects who had elevated triglyceride levels (above consecutive patients who had no data suggesting 2.3 mmol/l) and/or low HDL-C (below 0.9 mmol/l), any specific aetiology (including ethanol consumpwere instructed to follow a 'high-fat' diet which tion <40 g/week), and whose abdominal US examprovided 20% of total energy as monounsaturated ination was consistent with the diagnosis of fatty fat, <10% as saturated fat, 10% as polyunsaturated infiltration of the liver according to accepted crifat, and 45% as carbohydrate. The other patients teria,13 were referred to the metabolic clinic for were counselled to use the American Heart further evaluation.
Association diet which limits fat intake to <30%, saturated fat <10%, polyunsaturated fat <10% and monounsaturated 10-15% of total calories, with The data presented are the maximal values observed at presentation, in U/l. AST, serum aspartate-aminotransferase; ALT, serum alanine-aminotransferase; GGT, serum gamma-glutamyl transpeptidase; SAP, serum alkaline phosphatase. All patients had normal prothrombin time and normal serum albumin and bilirubin levels. 31.5±11.5 kg/m2 and 64% of the patients were * For 27 non-diabetic patients.
obese (BMI>27.8 in males and >27.3 kg/m2 in females).20 Abdominal obesity (defined in males as a waist/hip ratio >0.95 and in females as >0.8),14 (mostly lobular) and six of those had associated hepatic fibrosis which was grade 3 in two patients was found in 63% of the patients. Waist circumference was 101±6.7 and 105±7.7 cm for male only. No biopsy showed liver cirrhosis. A detailed fasting lipid profile was obtained for and female patients, respectively, and waist/hip ratio was 1.0±0.1 for both groups. Hypertension all patients (Table 2 ). Some kind of dyslipidaemia was detected in 90% of the patients. Elevation of (Á140/90 mmHg) was present in 58%, but drug therapy, where used, did not include medications triglycerides with or without low HDL-C or elevated total cholesterol levels was found in 73% of the known to be associated with fatty liver or dyslipidaemia.
patients. Low HDL-C levels, often with elevated triglyceride or total cholesterol levels, were detected The most consistent abnormality of serum liver enzymes (Table 1) , detected in almost all patients, in 68% of the patients. Altogether, hypertriglyceridaemia and/or low HDL-C was found in 41/48 (86%) was an elevation of about two-fold in ALT, whereas increased AST levels were noted in 77% of the of cases. The relative distribution of the lipid profile abnormalities is presented in Figure 1 . Fasting plasma patients, but to a lesser degree. Elevated GGT levels were found in 52% of the patients, sometimes glucose determinations or OGTT revealed diabetes in 21 cases (44%). In most of them (12/21, 57%), accompanied by an increased serum alkaline phosphatase in 15%. None of the patients had bilirubinaediagnosis of diabetes was not made prior to their presentation for the current evaluation. Of the mia, reduced serum albumin levels or prolongation of the prothrombin time. All patients had findings remaining 27 patients, IGT was found in 14 patients, and a further eight patients who showed an otherwise consistent with fatty infiltration by ultrasonography which is a highly accurate tool for the diagnosis of normal glucose response to the OGTT, manifested clearly elevated fasting insulin levels (Figure 2 ). fatty liver.4,21 In 16 of the 48 patients the diagnosis was confirmed by a liver biopsy (Table 3) . These Altogether, 90% of the patients had some abnormality in their glucose-insulin metabolism. Only five patients were randomly selected for biopsy and their clinical and laboratory profiles were not significantly had a normal response to an OGTT with normal fasting insulin levels (below the 90th percentile). The different from the remaining cohort (Table 3 ). The biopsies revealed marked steatosis in all specimens relative distribution of these findings is presented in Figure 2 . Patients with diabetes tended to be more (16/16). Eight patients had inflammatory changes 
002).
During the follow-up period, liver enzyme levels were reduced to some degree in all but two patients (46/48, 96%). In 25 patients (52%) they were reduced back to the normal range. The two patients who did not improve their LFTs were a 48-year-old obese male with diabetes (diagnosed by fasting hyperglycaemia) and dyslipidaemia with liver biopsy showing fatty infiltration (+2), and a 55-year-old obese woman with IGT and dyslipidaemia who refused a liver biopsy. Both patients did not lose weight and did not receive hypoglycaemic or lipid-lowering medications. None of the patients developed symp- revealed that the independent variables that were associated with improvement of ALT were the changes in HDL cholesterol levels ( p<0.01) and weight ( p=0.05).
Discussion
Our patients with 'primary' fatty liver had clinical features compatible with the insulin resistance syn- was characteristic of the insulin resistance syndrome: their waist circumference was significantly increased and values >95 cm for men and >80 cm for overweight than patients with normal glucose tolerance and normal insulin levels (BMI 106±9 vs.
women relate very closely to visceral fat,14,24 hyperinsulinaemia and insulin resistance.25,26 The uniformity 95±12, p=0.05), but the liver enzymes were similar regardless of the glucose tolerance status.
of the metabolic profile in this study can be explained by the careful metabolic evaluation. For example, in All patients were followed regularly, and the median follow-up period was 24 months (mean±SD 12/21 diabetic patients (57%), diabetes had not been diagnosed prior to the metabolic evaluation in this 32.5±31.6). Thirty-eight out of 48 patients (79%) achieved weight loss (mean 3.7 kg, range 1-10 kg). study. It was recently suggested that patients with NASH who are euglycaemic should be followed Of the diabetic patients, six were treated with one or two oral hypoglycaemic agents: (glyburide, 5
closely for the development of diabetes, but this was based on anecdotal experience,27 never before on a patients; metformin, 4 patients), one patient was treated with insulin, and 14 received dietary treatprospective study of consecutive patients presenting with NASH. Low HDL-C and/or hypertriglyceridaement only. Eight patients received lipid-lowering drugs; of these five received statins and three mia (mostly modest), which was found in the majority of our patients, is also a typical finding in patients fibric acid derivatives. Mean fasting blood glucose was reduced from 7.2±2.4 to 6.2±1.6 mmol/l with diabetes or insulin resistance.28 Previous studies of patients with NASH or fatty liver have not included one series, one third of the patients had significant fibrosis or cirrhosis,9 in contrast to another study detailed lipid profiles,5-10 nor was OGTT performed, and therefore the true prevalence of this dyslipidaewhere biopsies revealed only steatosis in almost all patients.10 In our group, underlying conditions were mia may have been underestimated.
The pathogenesis of hepatic steatosis remains carefully excluded and the patients (according to the representative liver histology obtained in a third) had unclear. Several of the recognized associated conditions, such as intestinal bypass surgery, steroid treatonly steatosis, some inflammation (in half) and lowgrade fibrosis. Previous studies in which the natural ment, and total parenteral nutrition, can cause a metabolic shift favouring lipogenesis rather than course of the disease is described were not aimed at examining the effect of therapeutic interventions.5-10 lipolysis, and lead to steatosis.2,12 Increased levels of free fatty acids are known to occur in patients with However, there are data suggesting that diet-induced weight reduction leads to biochemical and histo-NIDDM or insulin resistance, because of the reduced ability of insulin to suppress lipolysis.29,30 Resistance logical improvement.35,36 As the present study was designed to evaluate the effect on the liver of to the suppressive effect of insulin on the production of VLDL in the liver is another postulated defect in improvement of the metabolic profile, each patient was referred to a dietician for individualized counselinsulin-resistant states.30 Insulin resistance is commonly associated with obesity, but can exist indeling and follow-up. The results showed that dietary intervention was highly effective: an average moderpendently, as encountered in one of our cases, a lean female with Turner's syndrome, a syndrome ate weight reduction of 3.7 kg was associated with a marked improvement of the metabolic parameters known to be associated with insulin resistance as an early defect.31 This patient had marked steatosis, and and a decrease, often normalization, of liver enzymes. This is in contrast to previous work showing demonstrates that obesity is not a prerequisite. More substantial support for the role of insulin resistance that only a weight reduction of at least 10% could correct abnormal hepatic test results.35 Furthermore, in the pathogenesis of fatty liver comes from two previous studies that demonstrate a clear association our observations on the five patients treated with statins whose LFTs likewise improved, imply that the between fatty liver and insulin levels in both adults32 and children33 with fatty liver. ALT levels correlated use of statins in patients with dyslipidaemia and disturbed LFTs due to fatty liver is appropriate. significantly with fasting insulin levels, suggesting that hyperinsulinaemia is an important contributor
In conclusion, most of our 48 consecutive patients with 'primary' fatty liver had a characteristic clinical to the development of fatty liver, more crucial to the pathogenesis than anthropomorphic data, blood glupicture compatible with the insulin resistance syndrome including obesity with visceral fat deposition, cose or serum lipids. 33 Recently, a 'two-hit' hypothesis for the develophypertension, glucose intolerance and typical dyslipidaemia. Moreover, simple measures aimed at ment of steatohepatitis has been proposed. The first hit produces steatosis, the second, any source of improving metabolic profile, such as weight reduction and the use of anti-diabetic or lipid-lowering oxidative stress that increases lipid peroxidation and subsequently leads to increased liver damage. 34 drugs, were associated with marked reduction or normalization of liver enzyme levels in most patients, Factors which can produce a 'second hit' such as iron overload, alcohol, and drugs were conspicuously confirming the association, and suggesting that the natural course of this entity is benign and treatable. absent in our study group. For example, only two of our patients had (minimally) elevated iron levels, in contrast to 58% in Bacon et al.. 9 It was easier to exclude the effects of alcohol in our patients, since
